Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation.
In this paper, we examined in detail the ability of anti-1F7 to modulate 1F7 (CD26) surface expression as well as analyzed the functional relationship between the surface expression of CD3, CD2, and CD26 and human T cell activation. We showed that anti-1F7-induced modulation is an energy-dependent process that occurs via capping and internalization of the Ag-antibody complex. Although the recovery rate for Ag reexpression of 1F7 following optimal modulation is relatively delayed, reexpression of 1F7 is greatly accelerated following phorbol ester treatment. Most importantly, we demonstrated that modulation of the CD26 Ag leads to an enhancement in the proliferative activity of modulated human T cells treated with anti-CD3 or anti-CD2, which is preceded by an enhancement in Ca2+ mobilization. CD26 modulation also led to an increase in anti-CD3- or anti-CD2-mediated T cell clone proliferation. Finally, whereas modulation of the CD26 Ag has an effect on CD3- or CD2-induced T cell activation, modulation of the CD3/TCR complex inhibits the proliferative response of T cells incubated with anti-CD3 plus anti-1F7 or anti-CD2 plus anti-1F7. However, modulation of the CD2 structure does not affect anti-CD3- plus anti-1F7-induced human T cell activation. The above results thus provide additional evidence that the CD26 Ag plays an integral role in the regulation of human T cell activation.
Dang
N H
NH
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA.
Torimoto
Y
Y
Sugita
K
K
Daley
J F
JF
Schow
P
P
Prado
C
C
Schlossman
S F
SF
Morimoto
C
C
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000936:Antigen-Antibody Complex / Q000378:metabolism; D015703:Antigens, CD / Q000502:physiology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000502:physiology*; D001386:Azides / Q000494:pharmacology; D018801:CD2 Antigens; D017252:CD3 Complex; D002118:Calcium / Q000502:physiology; D018819:Dipeptidyl Peptidase 4; D004306:Dose-Response Relationship, Immunologic; D004705:Endocytosis; D005434:Flow Cytometry; D005459:Fluorides / Q000494:pharmacology; D006801:Humans; D007152:Immunologic Capping; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D010703:Phorbol Esters / Q000494:pharmacology; D011948:Receptors, Antigen, T-Cell / Q000502:physiology; D011971:Receptors, Immunologic / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D001386:Azides; D018801:CD2 Antigens; D017252:CD3 Complex; D010703:Phorbol Esters; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D018819:Dipeptidyl Peptidase 4; D005459:Fluorides; D002118:Calcium